NASDAQ:IMCC IM Cannabis Q2 2025 Earnings Report $0.14 +0.00 (+3.01%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$0.14 +0.00 (+0.80%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast IM Cannabis EPS ResultsActual EPS-$0.07Consensus EPS -$0.14Beat/MissBeat by +$0.07One Year Ago EPSN/AIM Cannabis Revenue ResultsActual Revenue$9.21 millionExpected Revenue$12.88 millionBeat/MissMissed by -$3.67 millionYoY Revenue GrowthN/AIM Cannabis Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time9:00AM ETUpcoming EarningsIM Cannabis' Q2 2026 earnings is estimated for Monday, August 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) IM Cannabis Earnings HeadlinesIM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note FinancingJuly 1, 2026 | prnewswire.comIM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 millionJune 18, 2026 | prnewswire.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)IM Cannabis Announces Form F-3 Resale Registration Statement FilingJune 9, 2026 | prnewswire.comIM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note FinancingJune 3, 2026 | prnewswire.comIM Cannabis Corp. Announces First Quarter 2026 Financial ResultsMay 13, 2026 | prnewswire.comSee More IM Cannabis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email. Email Address About IM CannabisIM Cannabis (NASDAQ:IMCC) Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles. The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners. Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.View IM Cannabis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
